TAS0728 is primarily investigated for its potential in cancer therapy, particularly targeting tumors that are driven by specific genetic mutations. It functions as a selective inhibitor, effectively blocking pathways that promote tumor growth and survival. This makes it a promising candidate for treating cancers that are resistant to conventional therapies. Clinical trials are ongoing to evaluate its efficacy and safety in patients with advanced solid tumors, focusing on its ability to inhibit key oncogenic drivers. Additionally, its targeted approach may reduce the side effects commonly associated with traditional chemotherapy, offering a more tolerable treatment option for patients. Research also explores its potential in combination therapies to enhance overall treatment outcomes.